

The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT)
PrOSPeCT is Omico’s landmark program that brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products. Through this initiative we’re opening up new treatment paths across Australia for people with difficult-to-treat cancers, including those with ovarian cancers, pancreatic cancers, sarcomas, and advanced and metastasic cancers.